SPX4,076.57-3.54 -0.09%
DIA344.34-1.81 -0.52%
IXIC11,482.45+14.45 0.13%

OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer

Benzinga · 11/16/2022 06:07
  • OncoSec Medical Incorporated (NASDAQ:ONCS) announced early clinical data from an investigator-sponsored trial of TAVO in combination with Bristol-Myers Squibb Co's (NYSE:BMY) intravenous Opdivo (nivolumab). 
  • TAVO is OncoSec's proprietary interleukin 12 (IL-12) encoding plasmid delivered by intratumoral electroporation (TAVO-EP).
  • The trial enrolled patients with high-risk operable locoregional advanced stage IIIB-D or stage IVA melanoma. 
  • Related: OncoSec Cuts Workforce, Prioritizes Pipeline.
  • A preoperative overall response rate was observed in 7 of 10 patients (70%) consisting of 4 patients with complete response (CR) and three patients with partial response (PR). 
  • Two patients had stable disease, and one showed progressive disease. 
  • One patient with a PR declined surgery due to a significant response after neoadjuvant treatment. 
  • At the time of surgery, 8 of 9 (88.9%) evaluated patients had a major pathologic response, and 6 of 9 patients (66.7%) had a pathological CR. No disease recurrence has been observed at a median follow-up of 7 months from the surgery date.
  • Overall, the combination treatment was well tolerated, and no patient discontinued neoadjuvant treatment due to toxicity. Patients continue to enroll.
  • Price Action: ONCS shares are up 1.99% at $4.10 during after-hours trading on Tuesday.